###begin article-title 0
Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin p 2
###xml 78 92 78 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Histopathology</italic>
###xml 92 94 92 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">49</bold>
Jass J R, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D & Young J (2006) Histopathology49, 121-131
###end p 2
###begin p 3
###xml 0 156 0 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a &#8216;fusion&#8217; pathway to colorectal cancer</bold>
Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer
###end p 3
###begin title 4
Aim
###end title 4
###begin p 5
To establish and explain the pattern of molecular signatures across colorectal polyps.
###end p 5
###begin title 6
Methods and results
###end title 6
###begin p 7
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 740 744 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 874 875 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Thirty-two sessile serrated adenomas (SSA), 10 mixed polyps (MP), 15 traditional serrated adenomas (SA), 49 hyperplastic polyps (HP) and 84 adenomas were assessed for mutation of KRAS and BRAF and aberrant expression of p53. The findings were correlated with loss of expression of O-6-methylguanine DNA methyltransferase (MGMT). KRAS mutation occurred more frequently (26.5%) than BRAF mutation (4.8%) in adenomas (P < 0.001) and particularly in adenomas with villous architecture (50%). Loss of expression of MGMT correlated with KRAS mutation in small tubular adenomas (P < 0.04). BRAF mutation was frequent in HPs (67%) and SSAs (81%), while KRAS mutation was infrequent (4% and 3%, respectively). Of MPs and SAs, 72% had either BRAF or KRAS mutation. Aberrant expression of p53 was uncommon overall, but occurred more frequently in MPs and SAs (12%) than adenomas (1%) (P < 0.04) and there was concordant loss of expression of MGMT.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
Molecular alterations that are characteristic of the serrated pathway and adenoma-carcinoma sequence can co-occur in a minority of advanced colorectal polyps that then show morphological features of both pathways. These lesions account for only 2% of colorectal polyps, but may be relatively aggressive.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
The traditional view of epithelial polyps of the colorectum envisages a larger non-neoplastic category of hyperplastic polyps (HPs) that can be safely ignored and a smaller category of neoplastic polyps or adenomas that are precancerous.1 With respect to adenomas, it is clear that the majority will not progress to colorectal cancer (CRC).2 The risk of cancer developing within an adenoma increases with size, grade of dysplasia (synonymous with intraepithelial neoplasia) and villosity.3 These features, together with polyp numbers, are also predictive of metachronous neoplasia and may therefore influence the decision to offer follow-up endoscopic surveillance.4 However, the grading of dysplasia and estimation of the extent of villous change may not be fully reproducible and it may be difficult to distinguish new from recurrent adenomas. Establishing a risk profile on the basis of the traditional features of adenoma is therefore not always straightforward.
###end p 11
###begin p 12
###xml 286 289 286 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 313 317 313 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 761 765 761 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 854 855 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 907 908 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 1019 1023 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1278 1279 1278 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
The addition of molecular profiling to polyp description offers hope of a more objective and therefore reproducible approach to the classification of colorectal adenomas. The genetic evolutionary paradigm envisages a linear sequence of changes beginning with bi-allelic inactivation of APC, followed by oncogenic KRAS mutation and culminating in inactivation of TP53 at the transition from adenoma to carcinoma.5 While there is good evidence that KRAS mutation is associated with advanced adenoma features6 and could therefore be used as objective evidence of aggression, this approach has a number of limitations. First, KRAS mutation also occurs frequently in dysplastic aberrant crypt foci (microadenomas) and in some small tubular adenomas, suggesting that KRAS mutation may initiate a subset of small adenomas with limited potential for progression.6,7 Second, around 70% of CRCs lack mutation of KRAS.8 From this it follows that most of the precancerous lesions that eventually become cancers do not in fact have KRAS mutation. There is increasing evidence that CRC evolves through a number of pathways and the traditional adenoma-carcinoma sequence, with its accompanying genetic steps, provides a surprisingly narrow window of understanding of this multipathway reality.9
###end p 12
###begin p 13
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
In recent years, the fundamental division of colorectal polyps into precancerous adenomas and innocent HPs has begun to erode and the concept of an alternative serrated pathway has gained support. This revision began with the description of an intermediate lesion described as serrated adenoma (SA).10 Initially, however, SA was not conceived as an intermediate category of polyp but essentially as an adenoma with a superimposed serrated architecture that conferred only a superficial likeness to a HP.10 Additionally, the mixed polyp (MP) was perceived as a chance collision between a HP and an adenoma, giving a combined polyp. These preliminary interpretations did not represent a major departure from the traditional classification of colorectal polyps but preserved the fundamental distinction of neoplastic adenomas versus non-neoplastic HPs.
###end p 13
###begin p 14
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 141 148 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
Subsequently, it was argued that HP and SA are related lesions.11 The latter could arise within the former (giving a MP) or could develop as de novo SA but through mechanisms shared with HPs. This proposal subsequently received strong support through the demonstration of molecular alterations common to both types of serrated polyp, notably mutation of BRAF and extensive DNA methylation.12 This viewpoint was consolidated through the formal recognition of two largely independent pathways of colorectal tumorigenesis: (i) the traditional adenoma-carcinoma sequence associated with chomosomally unstable CRCs,13 and (ii) the 'serrated pathway' culminating in CRCs with DNA microsatellite instability (MSI), mutation of BRAF and extensive DNA methylation.12,14-20
###end p 14
###begin p 15
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 493 532 493 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O-6-methylguanine DNA methyltransferase</italic>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 578 582 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
This paper explores the possibility that the early evolution of colorectal cancer is not limited to two essentially independent pathways, but often combines components of these pathways. Indeed, the successful 'fusion' of the hyperproliferation and crypt fission that characterize adenomas21 with the inhibition of apoptosis that has been linked with serrated polyps22,23 may generate lesions with enhanced aggressiveness. Specifically, it is suggested that methylation of the DNA repair gene O-6-methylguanine DNA methyltransferase (MGMT), mutation of KRAS and inactivation of TP53 provide critical combinations of molecular 'cross-over' between the two pathways that occur at the stage of precancerous polyps.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Tissues
###end title 17
###begin p 18
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 882 883 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 971 972 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1000 1001 1000 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1014 1015 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1043 1044 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 1150 1152 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 1319 1321 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1377 1381 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1426 1428 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 1429 1431 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1432 1434 1432 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 1813 1815 1813 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
The colorectal polyps used in this study were from a previously characterized subset of a consecutive series of 1250 colonoscopically derived lesions.24 The study group included all SAs (sessile and traditional) and MPs and a subset of conventional adenomas and HPs. The previous study analysed proliferative indices and there was therefore selection of HPs that were large and well-oriented and likely to provide sufficient numbers of longitudinally sectioned crypts. Polyps were eliminated from the present study if there was insufficient residual tissue, blocks contained more than one polyp, polyps contained foci of invasive cancer, or there was failure of DNA amplification for both the BRAF and KRAS mutation assays. Fifteen additional polyps from the parent series generated a total study group of 190 polyps. These were reviewed by the first author and classified as: HPs (n = 49), tubular adenomas (TAs) (n = 62), tubulovillous and villous adenomas (TVAs/VAs) (n = 22), sessile SAs (SSAs) (n = 32), MPs (n = 10) and traditional SAs (n = 15). SSA has also been termed sessile serrated polyp and serrated polyp with atypical proliferation.17,25-27 SSA is distinguished from HP on the basis of greater size, aberrant architecture, atypical proliferation, hypermucinous epithelium, predilection for proximal colon25 and molecular features including a higher frequency of BRAF mutation and more extensive DNA methylation.14,16,17 However, the combination of architectural and cytological changes is insufficient for a diagnosis of dysplasia. Serrated polyps with dysplasia include MPs and SAs. MPs may be conceived as a combined lesion that includes: (i) a serrated component that is non-dysplastic and resembles HP or SSA, and (ii) a dysplastic component that may resemble either SA or conventional adenoma.28 For the purposes of this study, lesions were also included as MPs if they comprised separate serrated and non-serrated components that were both dysplastic. SAs are homogeneous lesions in which there is epithelial serration reminiscent of a HP or SSA together with architectural and cytological changes warranting a diagnosis of dysplasia. The cytological atypia of SA may appear similar to that of conventional adenoma in which nuclei are elongated, hyperchromatic and pseudostratified. However, some SAs may be characterized by non-adenomatous forms of dysplasia in which the nuclei are enlarged, ovoid, vesicular and contain a prominent nucleolus, while the cytoplasm is relatively abundant and eosinophilic. The anatomical site of polyps was grouped as proximal colon (up to splenic flexure) versus distal colon and rectum combined. The study was approved by the Institutional Review Board of the Faculty of Medicine, McGill University.
###end p 18
###begin title 19
Dna extraction
###end title 19
###begin p 20
###xml 502 503 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 502 503 478 479 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
Genomic DNA was extracted from archival paraffin-embedded tissue sections using DNeasy Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions except for the omission of xylene treatment. Briefly, five 4-microm non-microdissected sections (polyps were generally accompanied by little normal mucosa) and 180 microl of ATL buffer were dissolved at 80degreesC and then digested overnight with 20 microl of proteinase K at 55degreesC. Following centrifugation at 2000 r.p.m. (300 g) for 5 min, the lower phase was applied to a DNeasy tissue column. Bound DNA was washed by centrifugation through ethanol and then eluted from the column using AE buffer.
###end p 20
###begin title 21
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
KRAS and BRAF mutations
###end title 21
###begin p 22
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
KRAS mutation analysis at codons 12 and 13 was performed using direct automated sequencing of a fragment containing codon 12 and 13 in exon 1 of the KRAS gene, amplified using a touchdown polymerase chain reaction (PCR) cycle and hotstart protocol. PCR products were initially purified and then directly sequenced using BigDye version 3.1 dye terminators and an ABI 3100 DNA fragment analyser. The sequence at codon 12 and 13 was determined using Mutation Surveyor (SoftGenetics, State College, PA, USA) software.
###end p 22
###begin p 23
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 375 376 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 731 732 727 728 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 758 759 754 755 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 789 790 785 786 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
BRAF mutation analysis at codon 600 (V600E; formerly V599E) was performed by a real-time PCR-based allelic discrimination method as previously described.29 Briefly, real-time PCR was performed using allele-specific primers designed to amplify selectively the wild-type (T1796) and mutant (A1796) BRAF alleles. The primer sequences were as follows: V, 5'-GTGATTTTGGTCTAGCTACtGT; E, 5'-CGCGGCCGGCCGCGGCGGTGATTTTGGTCTAGCTACcGA; AS, 5'-TAGCCTCAATTCTTACCATCCAC. PCR amplification and melting curve analysis were performed on a Rotor-gene 3000 (Corbett Research, NSW, Australia). Genomic DNA was amplified in a 15-microl volume containing 1 x Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA), forward primer V (300 nm), forward primer E (900 nm) and reverse primer AS (300 nm). The cycling conditions were as follows: 50degreesC for 2 min, 95degreesC for 2 min, 40 cycles of 95degreesC for 15 s and 60degreesC for 60 s. After amplification, samples were subjected to a temperature ramp from 60degreesC to 99degreesC, rising 1degreesC each step. For wild-type samples, single peaks were observed at 80degreesC while samples containing mutant alleles produced single peaks at 85degreesC.
###end p 23
###begin title 24
p53 immunohistochemistry and scoring
###end title 24
###begin p 25
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 549 550 545 546 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 277 282 <span type="species:ncbi:42554">tetra</span>
###xml 435 439 <span type="species:ncbi:9925">goat</span>
This was undertaken on all adenomas and all serrated polyps with dysplasia (traditional SA and MP). Most of these polyps had been immunostained previously for MGMT.24 Following deparaffinization and rehydration of 4-microm sections and antigen retrieval using ethylene diamine tetra-acetic acid and microwaving, the sections were subjected to peroxidase blockade (Dako EnVision bottle 1; Mississauga, Canada) and then incubated in 10% goat serum to minimize non-specific staining. They were subsequently incubated with the primary anti-p53 antibody (DO-7, from DakoCytomation, Mississauga, Canada) at a dilution of 1 : 100 for 60 min at 37degreesC. After washing, the sections were incubated with secondary antibody (EnVision bottle 2) for 30 min, washed again and then developed with the chromogen AEC for 30 min. Finally, the sections were counterstained with Gill's haematoxylin. Polyps were scored as showing loss of expression of MGMT if there was complete absence of nuclear expression throughout one or more crypts. Polyps were scored as positive for aberrant p53 expression if there were distinct subclones characterized by strong nuclear expression that implicated at least 50% of nuclei.
###end p 25
###begin title 26
Statistics
###end title 26
###begin p 27
###xml 25 26 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 56 57 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 129 130 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data were analysed by chi2 test, Fisher's exact test or T-test, as appropriate, using SAS software, version 8.2 (Cary, NC, USA). P-values < 0.05 were interpreted as significant.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
KRAS and BRAF mutation
###end title 29
###begin p 30
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 281 285 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 357 361 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 444 448 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 495 499 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 504 508 492 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 678 682 666 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 687 691 675 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 735 739 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 788 792 776 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 797 801 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 862 869 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
DNA failed to amplify in the KRAS assay for one SSA and one TA < 10 mm. Overall, 34 of 188 polyps (18%) had mutation of KRAS. Twenty-eight mutations were in codon 12 (20 G-->A, seven G-->T and one G-->C) and six mutations were in codon 13 (all G-->A). One serrated adenoma had two KRAS mutations in codon 12 (G-->T at position 35 and T-->G at position 36). BRAF mutation at V600E could be assessed in all polyps except for a single TA < 10 mm. BRAF mutation was found in 82 of 189 polyps (43%). BRAF and KRAS mutations were negatively correlated, with only four polyps having both mutations (two TAs, one TVA and one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
###end p 30
###begin p 31
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Frequency of KRAS and BRAF mutation and loss of expression of O-6-methylguanine DNA methyltransferase (MGMT) by polyp type
###end p 31
###begin p 32
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Mutation frequencies for both KRAS (P < 0.0001) and BRAF (P < 0.0001) are distributed differently across the seven classes of polyp (see Results for individual comparisons). Distribution of MGMT loss differs across the seven classes of polyp (P < 0.001).
###end p 32
###begin p 33
Note: no result for KRAS in one sessile serrated adenoma (SSA) and one tubular adenoma (TA) or for BRAF in one TA. MGMT immunstaining not performed in 15 polyps (seven HPs, one SSA, one MP and six TAs).
###end p 33
###begin p 34
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 83 90 83 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
KRAS mutation occurred in 26.5% and BRAF mutation in 4.8% of adenomas (all types) (Table 1) (P < 0.0001). TVAs/VAs were more likely to have KRAS mutation (50%) than TAs < 10 mm (18%) (P < 0.004) or TAS > 10 mm in diameter (17%) (P < 0.02). In the case of TAs there was a trend for KRAS mutation to occur more frequently in polyps from the proximal colon (P = 0.08) and in females (P = 0.07).
###end p 34
###begin p 35
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 173 180 173 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 385 386 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 183 190 <span type="species:ncbi:9606">Patient</span>
SSAs were more likely to have BRAF mutation (81%) than either SAs (33%) (P < 0.001) or MPs (40%) (P < 0.02). KRAS mutation was infrequent among both SSAs (3%) and HPs (4%) (Table 1). Patient age, gender and anatomical location were not predictors of BRAF mutation in either SSAs or HPs. The mean age of subjects with SSAs (64 years) differed from that of subjects with HPs (55 years) (P < 0.001).
###end p 35
###begin p 36
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 170 177 170 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 592 603 592 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1A,B</xref>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 711 722 711 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1C,D</xref>
###xml 725 729 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 801 802 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 812 816 812 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 890 891 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 941 945 941 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
BRAF and KRAS mutations were distributed in roughly similar proportions across MPs (90% had either BRAF or KRAS mutation) and SAs (60% had either BRAF or KRAS mutation) (Table 1). The frequent finding of either BRAF or KRAS mutations in both types of serrated polyp indicated that MPs and SAs might be heterogeneous lesions. These 25 serrated polyps with dysplasia were therefore grouped differently. Group A polyps (n = 16) included a non-dysplastic serrated component and/or dysplastic epithelium in which the architectural and cytological changes were more reminiscent of HP than adenoma (Figure 1A,B). Group B polyps (n = 9) comprised serrated polyps in which the epithelial dysplasia appeared adenomatous (Figure 1C,D). BRAF mutation occurred in 10/16 Group A polyps but only 1/9 Group B polyps (P < 0.03). KRAS mutation occurred in only 3/16 Group A polyps but in 5/9 Group B polyps (P = 0.06). In each of the five Group B polyps with KRAS mutation, the adenomatous component showed both villous change and serration.
###end p 36
###begin p 37
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 400 401 400 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 561 564 561 564 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C,D</bold>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 861 864 861 864 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E,F</bold>
###xml 904 908 904 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
A, Serrated adenoma (SA) (BRAF mutation) with a 'hyperplastic' appearance but with architectural and cytological features of a non-adenomatous form of dysplasia. The latter include marked epithelial serration and surface papillarity and nuclei that are ovoid, vesicular and contain a prominent nucleolus (inset). The columnar cells (inset) contain apical mucin droplets, similar to sessile SA (SSA). B, Mixed polyp (BRAF mutation) comprising SSA (left) and SA with high-grade dyplasia showing back-to-back glands (right) and aberrant expression of p53 (inset). C,D, Two mixed polyps (MPs) (both SA/tubulo-villous adenoma and with KRAS mutation) in which the serrated epithelium has an adenomatous appearance as evidenced by elongated hyperchomatic nuclei with marked stratification and a dark amphophilic cytoplasm. The pure adenomatous component is not shown. E,F, Low- and medium-power images of a SA (KRAS mutation) in which complex microacini have resulted in markedly serrated epithelial contours. The epithelium comprises numerous goblet cells and absorptive-type columnar cells with eosinophilic cytoplasm and is reminiscent of the goblet cell variant of hyperplastic polyp. These examples illustrate the range of appearances and genetic changes that are encompassed by 'traditional' SA.
###end p 37
###begin p 38
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 572 583 572 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1E,F</xref>
With respect to the 25 serrated polyps with dysplasia, only five occurred in the proximal colon (up to the splenic flexure). Two of these had BRAF mutation (both Group A) and two had KRAS mutation (both Group B). Seven of the 11 BRAF mutations occurred in polyps derived from the left colon or rectum (remaining two polyps with BRAF mutation from site unknown). The three Group A SAs with KRAS mutation (all from the left colon or rectum) comprised numerous goblet cells and adjacent cells with eosinophilic cytoplasm and no mucin production or microvesicular appearance (Figure 1E,F). These SAs therefore resembled the goblet cell variant of HP.
###end p 38
###begin title 39
Loss of expression of mgmt
###end title 39
###begin p 40
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 172 179 172 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 641 645 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Loss of expression of MGMT was distributed differently (P < 0.001) across the different types of polyps, being observed most frequently among MPs, TA > 10 mm and TVAs/VAs (Table 1). There was no correlation between loss of expression of MGMT and either KRAS or BRAF mutation across the full range of polyp types. However, among TAs < 10 mm, KRAS mutation occurred in 3/25 (12%) adenomas with no MGMT loss but in 4/8 (50%) adenomas with MGMT loss (P < 0.04). Since there were few KRAS mutations in this subset and most KRAS mutations (5/7) were G-->A, it was not possible to demonstrate an association between MGMT loss and G-->A mutation in KRAS.
###end p 40
###begin title 41
Aberrant expression of p53 and correlation with MGMT loss
###end title 41
###begin p 42
###xml 276 285 276 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1B</xref>
###xml 300 308 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 586 596 586 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figures 1B</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
Sixty-two TAs, 22 TVAs/VAs, 15 SAs and 10 MPs were immunostained for p53. Weak expression of nuclear p53 occurred frequently within the proliferative compartment in all types of polyps and was ignored. Aberrant p53 expression was observed in only four polyps: one TA, one MP (Figure 1B) and two SAs (Figure 2). Overall, only 1/84 (1%) conventional adenomas showed aberrant expression of p53 compared with 3/25 (12%) serrated polyps with dysplasia (P < 0.04). In the latter, aberrant p53 expression coincided with high-grade dysplasia and reduced or complete loss of expression of MGMT (Figures 1B and 2). The TA with aberrant p53 expression had normal expression of MGMT.
###end p 42
###begin p 43
###xml 66 67 66 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
High-power field of a serrated adenoma with high-grade dysplasia (A) in which there is aberrant nuclear expression of p53 (B) and loss of nuclear expression of O-6-methylguanine DNA methyltransferase (C).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 233 241 <span type="species:ncbi:9606">patients</span>
The scientific basis for the prevention of cancer depends upon an understanding of early events in pathogenesis, including the mechanisms underlying initiation and growth of precancerous polyps. Recommendations for the management of patients with colorectal polyps currently recognize only a single principal type of clinically important polyp: the adenoma. The current study includes additional types of polyp that are likely to have malignant potential, namely serrated polyps with (MP and SA) and without (SSA) dysplasia. This discussion will focus first on adenomas, second on non-dysplastic serrated polyps and will then conclude with the concept that features of these two types of polyp can co-occur or become 'fused' in subtypes of advanced polyps with mixed cytomorphology (hyperplastic and dysplastic) and a serrated and/or villous architecture.
###end p 45
###begin title 46
Adenomas
###end title 46
###begin p 47
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 383 387 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 722 726 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 756 760 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 844 848 844 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 907 911 907 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
The adenomas in this study were grouped as TAs < 10 mm, TAs > 10 mm and TVAs/VAs. Overall, KRAS mutation occurred in 26.5% of adenomas while BRAF mutation was detected in only 4.8%. Three of the four BRAF mutations occurred in adenomas that also had KRAS mutation. It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.12,16,30 Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.14,31 The assay for BRAF mutation used in this study was highly sensitive and it is possible that the mutation was being identified in normal mucosa included with the polyp. KRAS mutation may occur within apparently normal colorectal mucosa and the same could apply to BRAF.32 Therefore, the finding of BRAF mutation in a small subset of adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
###end p 47
###begin p 48
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 431 435 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 711 715 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 939 943 939 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1053 1057 1053 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1179 1180 1179 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 1266 1273 1266 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1417 1421 1417 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1459 1463 1459 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1705 1707 1705 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 321 333 <span type="species:ncbi:9606">participants</span>
###xml 1509 1517 <span type="species:ncbi:9606">patients</span>
In previous studies of KRAS in colorectal adenomas, mutation has been associated negatively with flat and depressed TAs and positively with polypoid appearance, increasing size, dysplasia, villous change and synchronous colorectal cancer.6,33-35 In by far the largest study, which included 738 adenomas obtained from 639 participants in a dietary intervention trial, multivariate analysis showed that the independent predictors of KRAS mutation were age of subject, presence of villous architecture and high-grade dysplasia, but not size of adenoma.6 It is well known that adenoma size, dysplasia and villous architecture are interrelated and account has to be taken of this in assessing results. In this study KRAS mutation occurred with the same frequency in small (18%) and large (17%) adenomas but was significantly more frequent in adenomas that included a villous architecture (50%). A previous study showed a very high frequency of KRAS mutation (93%) in flat adenomas with a tubulovillous architecture.34 We would agree with the suggestion that KRAS mutation is linked with the development of villous change and does not influence adenoma growth in an independent manner.6 In this study, high-grade dysplasia was diagnosed only when it amounted to carcinoma in situ. This was observed in none of the 84 adenomas but in four serrated polyps, of which three showed aberrant expression of p53 and the fourth had KRAS mutation. Age was not a predictor of KRAS mutation in this study. However, many of the patients were undergoing continuing colonoscopic surveillance for colorectal polyps and it is known that after clearance of large polyps, time is required for the growth of newly initiated polyps.36 This could explain why adenomas were smaller in subjects aged > 60 years than in subjects aged < 60 years (data not shown).
###end p 48
###begin title 49
Non-dysplastic serrated polyps: HP and SSA
###end title 49
###begin p 50
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 593 597 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 1007 1009 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1009 1013 1009 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1098 1102 1098 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1333 1335 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
Non-dysplastic serrated polyps comprise conventional HPs and the variant lesion which has been described as SSA. In this study, SSAs accounted for approximately 3% of the overall series of polyps and were more age-related than HPs. Importantly, SSAs have been linked with the subset of colorectal cancer with BRAF mutation, DNA methylation, MSI and serrated architecture.14,18,37 In this study there was a high frequency of BRAF mutation in conventional HPs (67%) as well as in SSAs (81%). Previous reports have shown very similar results for BRAF mutation in SSA,16 but higher frequencies of KRAS mutation and lower frequencies of BRAF mutation in HPs.12,16,38 As mentioned in Materials and methods, there had been selection of larger HPs in an earlier cell kinetic study involving the same material. Large HPs are more likely to include the subset described as 'microvesicular', in which the columnar cells contain apical mucin droplets within small vesicles while goblet cells are rendered inconspicuous.25BRAF mutation occurs more frequently in the microvesicular variant of HP.16 By contrast, KRAS mutation occurs much more commonly in the goblet cell variant of HP, which is usually small, located in the left colon or rectum and deviates minimally from normal colorectal mucosa in terms of differentiation and architecture.16,25 The latter were under-represented in this series (details not shown).
###end p 50
###begin title 51
dysplastic serrated polyps: MP and SA
###end title 51
###begin p 52
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 733 748 733 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1A,B,E,F</xref>
###xml 788 799 788 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1C,D</xref>
###xml 1437 1441 1437 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1498 1499 1498 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1539 1543 1539 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1586 1587 1586 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Serrated polyps with dysplasia, i.e. MPs and SAs, together comprised only 2% of the overall consecutive series of 1250 polyps. While mutation of KRAS and BRAF was associated with conventional adenoma and SSA, respectively (see above), BRAF and KRAS mutation occurred with similar frequency in both MPs (40% and 50%, respectively) and SAs (33% and 27%, respectively). In the literature, the frequency of BRAF and KRAS mutation in MP or SA has ranged from 36 to 100% and from 0% to 60%, respectively.12,16,39-42 These findings indicate that this subset of colorectal polyps is likely to be heterogeneous in terms of its molecular origins. These polyps were therefore reclassified according to their resemblance to HP or SSA (Group A) (Figure 1A,B,E,F) or to conventional adenoma (Group B) (Figure 1C,D). Particular histological features among the Group A polyps were: marked serration, a papillary or villous architecture, a relatively abundant eosinophilic cytoplasm, columnar cells with apical mucin droplets, nuclei that were enlarged, ovoid, vesicular and contained a prominent nucleolus, and adjacent non-dysplastic serrated polyp. Particular histological features among the Group B polyps were: some glandular serration, frequent villous change and epithelial dysplasia that appeared adenomatous (cytoplasmic basophilia and nuclei that were elongated, pseudostratified and hyperchromatic without a prominent nucleolus). Importantly, BRAF mutation occurred more frequently among Group A polyps (P < 0.03), whereas there was a trend for KRAS to be more frequent among Group B polyps (P = 0.06).
###end p 52
###begin p 53
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 726 737 726 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1E,F</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
The preceding findings indicate that serrated polyps with dysplasia evolve through at least two independent histogenetic pathways. Group A polyps are likely to be initiated by BRAF mutation and are serrated lesions at the outset. Group B polyps may begin as conventional adenomas and then become serrated and villous following mutation of KRAS. There may be instances in which KRAS mutation can initiate lesions which are serrated at the outset and become dysplastic. While this suggestion remains speculative, it may apply to the Group A serrated polyps that show a distinct likeness to the goblet cell variant of HP in which columnar cells are eosinophilic and lack mucin-filled microvesicles and KRAS mutation is frequent (Figure 1E,F).16,25 The literature refers to the concept of 'traditional' SA.43 Based on the current findings, it is likely that several mechanisms can account for adenomatous lesions with glandular serration and that 'traditional' SA is not a single entity.
###end p 53
###begin title 54
Concept of 'fusion' pathways to crc
###end title 54
###begin p 55
###xml 169 176 169 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 248 255 248 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 531 538 531 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 858 862 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 896 900 896 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1107 1114 <span type="species:ncbi:9606">patient</span>
Colorectal polyps have traditionally been classified into distinct histogenetic types that may progress to CRC through independent pathways of colorectal tumorigenesis (Table 2). However, in addition to the two 'classical' pathways to CRC shown in Table 2, there may be 'fusion' pathways that combine mechanisms associated with both adenomas and serrated polyps. This would explain why many CRCs display phenotypes associated with serrated polyps as well as adenomas.44 Three possible examples of such fusion pathways are shown in Table 3. It is difficult to observe directly the actual point of transition from benign to malignant colorectal lesions. Once the key rate-limiting step is achieved it is likely that the transition to cancer occurs rapidly and the precursor lesion is then overtaken by the malignancy. Changes leading to inactivation of either TP535 or the DNA mismatch repair gene MLH113 are likely to be two such rate-limiting mechanisms. Only a single instance of loss of expression of MLH1 was observed in the present series of polyps and the adenoma in question was inferred to be from a patient with Lynch syndrome.24
###end p 55
###begin p 56
Concept of discrete colorectal lesions and progression to colorectal cancer via independent pathways
###end p 56
###begin p 57
ACF, Aberrant crypt foci (hyperplastic or dysplastic); HP, hyperplastic polyp; SSA, sessile serrated adenoma; SA, serrated adenoma; TA, tubular adenoma.
###end p 57
###begin p 58
Inactivation of MLH1 and TP53 is associated with malignant progression.
###end p 58
###begin p 59
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
'Fusion' pathways brought about by the sequential alteration of genes (linked to separate lesions and pathways in Table 2) and with the second alteration associated with a superimposed morphology
###end p 59
###begin p 60
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
MGMT inactivation predisposes to G:T mismatches and chromosomal instability through futile cycles of excision and repair as well as to mutation of KRAS and TP53.9 Partial methylation of MLH1 may also lead to low-level microsatellite instability.37
###end p 60
###begin p 61
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 557 564 557 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 840 844 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 855 864 855 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1B</xref>
###xml 975 979 975 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1087 1094 1087 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
The interpretation of immunostaining for p53 is problematic insofar as increased expression of the wild-type protein occurs in areas of increased proliferation and must be distinguished from the diffuse and strong nuclear staining associated with retained mutant protein. However, several studies have described low frequencies of p53 expression in TAs with low-grade dysplasia45,46 and even in VAs.47 Conversely, there is general agreement that aberrant p53 expression is closely associated with the presence of high-grade dysplasia amounting to carcinoma in situ.34,46,48 Aberrant retention of presumed mutant nuclear p53 was rarely observed in the present series, although it occurred more frequently in serrated polyps with dysplasia (12%) than in adenomas (1%). One of the polyps with aberrant expression of p53 was a mixed polyp with BRAF mutation (Figure 1B). Had it not been removed, this polyp may have progressed within a short time frame to the subset of CRC with BRAF mutation, DNA methylation, TP53 mutation and DNA microsatellite stable status (a 'fusion' pathway shown in Table 3).49,50
###end p 61
###begin p 62
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 367 375 367 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 672 676 672 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 691 695 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 802 806 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
Loss of expression of the DNA repair gene MGMT is associated with methylation of the promoter region45,51,52 and the latter change has been linked causatively with G:C to A:T transition mutations in TP53.53 In the present study, complete or partial loss of expression of MGMT coincided with aberrant nuclear expression of p53 in three serrated polyps with dysplasia (Figure 2), but not in the single tubular adenoma with aberrant p53 expression. Only one previous study has attempted to correlate MGMT and p53 expression in colorectal polyps.45 In that study, 4.3% of adenomas showed aberrant p53 expression but none had loss of MGMT. It is possible that the link between MGMT silencing and TP53 mutation is more evident in the serrated pathway than in the adenoma-carcinoma sequence. The frequency of TP53 mutation in SAs has ranged from 5 to 50% in the literature.39,41,54 Although a link between MGMT loss and aberrant expression of p53 is supported by the present findings, it should be noted that only a small number of polyps showed these changes concurrently.
###end p 62
###begin p 63
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 748 752 748 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 909 913 909 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">58</xref>
###xml 998 1002 998 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1029 1030 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 1133 1135 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 1300 1304 1300 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1324 1327 1324 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
###xml 1345 1352 1345 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
KRAS mutation has been linked to the initiation of hyperplastic aberrant crypt foci and small HPs7,38,55 and is therefore closely associated with the development of glandular serration. While the acquisition of KRAS mutation is also observed in adenomas, this change is correlated with the development of a villous architecture and in some cases the presence of epithelial serration (see Discussion of Group B serrated polyps above). It may therefore be conceptually correct to view KRAS mutation as adding a serrated molecular signature to the traditional adenoma and hence providing an additional 'fusion' pathway. However, a mechanistic link between KRAS mutation and the morphogenesis of serration and villous change remains to be established. MGMT is again implicated in this second type of 'fusion' since methylation and inactivation of this DNA repair gene has been linked to G:C to A:T transitions in KRAS.56-58 In this study there was an association between loss of expression of MGMT and KRAS mutation among small TAs (P = 0.04) but not in the other polyp categories. Methylation of MGMT occurs in normal colorectal mucosa,59 as well as in polyps, and is therefore unlikely to serve as a key rate-limiting step in the transition to malignancy. A possible third 'fusion' pathway implicating KRAS and methylation of APC60 is included in Table 3.
###end p 63
###begin p 64
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 451 455 451 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
In summary, MPs and SAs account for only about 2% of colorectal polyps. Nevertheless, those serrated polyps with dysplasia show frequent mutation of either KRAS or BRAF and frequent loss of expression of MGMT (particularly MP). Additionally, four of 25 (16%) showed high-grade dysplasia and in three of these there was concordant aberrant nuclear expression of p53. Along with SSAs, these rare polyps may serve as the precursors of sporadic CRCs with BRAF mutation and DNA methylation (with and without DNA MSI) and a subset of CRCs with KRAS mutation. Their malignant potential is explained by the accumulation of genetic alterations that may in turn depend upon the inactivation of the DNA repair gene MGMT.28 The importance of these 'fusion' polyps as cancer precursors may be under-appreciated because critical rate-limiting changes governing malignant transition, particularly in association with loss of function of MLH1 of p53, occur rapidly and can rarely be 'caught in the act'.
###end p 64
###begin p 65
This study was supported by the Canadian Institutes of Health Research (MOP-67206). We thank Hassmig Minassian for technical support.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
The evolution of cancer of the colon and rectum
###end article-title 67
###begin article-title 68
Risk of colorectal cancer in adenoma-bearing individuals within a defined population
###end article-title 68
###begin article-title 69
Pathology of colorectal adenomas: a colonoscopic survey
###end article-title 69
###begin article-title 70
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas
###end article-title 70
###begin article-title 71
Genetic alterations during colorectal-tumor development
###end article-title 71
###begin article-title 72
Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics
###end article-title 72
###begin article-title 73
Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis
###end article-title 73
###begin article-title 74
Evolution of colorectal cancer: change of pace and change of direction
###end article-title 74
###begin article-title 75
Emerging concepts in colorectal neoplasia
###end article-title 75
###begin article-title 76
Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia
###end article-title 76
###begin article-title 77
DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer?
###end article-title 77
###begin article-title 78
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas
###end article-title 78
###begin article-title 79
Lessons from hereditary colorectal cancer
###end article-title 79
###begin article-title 80
BRAF mutation and CpG island methylation: an alternative pathway to colorectal cancer
###end article-title 80
###begin article-title 81
Concordant CpG island methylation in hyperplastic polyposis
###end article-title 81
###begin article-title 82
BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status
###end article-title 82
###begin article-title 83
Hyperplastic (serrated) polyps of the colorectum. Relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype
###end article-title 83
###begin article-title 84
Serrated adenoma of the colorectum and the DNA-methylator phenotype
###end article-title 84
###begin article-title 85
Hyperplastic-like colon polyps that preceded microsatellite unstable adenocarcinomas
###end article-title 85
###begin article-title 86
Colorectal carcinoma associated with serrated adenoma-prevalence, histological features, and prognosis
###end article-title 86
###begin article-title 87
APC in the regulation of intestinal crypt fission
###end article-title 87
###begin article-title 88
Proliferation kinetics and apoptosis of serrated adenoma of the colorectum
###end article-title 88
###begin article-title 89
Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis
###end article-title 89
###begin article-title 90
Demographic and pathological characteristics of serrated polyps of colorectum
###end article-title 90
###begin article-title 91
Morphologic reappraisal of serrated colorectal polyps
###end article-title 91
###begin article-title 92
###xml 34 40 <span type="species:ncbi:9606">humans</span>
Serrated adenomatous polyposis in humans
###end article-title 92
###begin article-title 93
Hyperplastic polyps and colorectal cancer: is there a link?
###end article-title 93
###begin article-title 94
Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon
###end article-title 94
###begin article-title 95
BRAF mutation and variable levels of microsatellite instability characterize a syndrome of familial colorectal cancer
###end article-title 95
###begin article-title 96
Tumorigenesis: RAF/RAS oncogenes and mismatch repair status
###end article-title 96
###begin article-title 97
###xml 60 65 <span type="species:ncbi:9606">human</span>
BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms
###end article-title 97
###begin article-title 98
###xml 97 105 <span type="species:ncbi:9606">patients</span>
K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients
###end article-title 98
###begin article-title 99
Involvement of APC and K-ras mutation in non-polypoid colorectal tumorigenesis
###end article-title 99
###begin article-title 100
Cell kinetics, p53 and bcl-2 expression, and c-Ki-ras mutations in flat-elevated tubulovillous adenomas and adenocarcinomas of the colorectum: comparison with polypoid lesions
###end article-title 100
###begin article-title 101
Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa
###end article-title 101
###begin article-title 102
Colorectal cancer screening: clinical guidelines and rationale
###end article-title 102
###begin article-title 103
Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer
###end article-title 103
###begin article-title 104
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ras</italic>
###xml 37 42 <span type="species:ncbi:9606">human</span>
High frequency of K-ras mutations in human colorectal hyperplastic polyps
###end article-title 104
###begin article-title 105
Molecular differences between serrated and conventional colorectal adenomas
###end article-title 105
###begin article-title 106
Genetic alterations in serrated adenomas: comparison to conventional adenomas and hyperplastic polyps
###end article-title 106
###begin article-title 107
Molecular characteristics of serrated adenomas
###end article-title 107
###begin article-title 108
Tracing origin of serrated adenomas with BRAF and KRAS mutations
###end article-title 108
###begin article-title 109
Serrated polyps of the large intestine. A morphologic and molecular review of an evolving concept
###end article-title 109
###begin article-title 110
Relation between metaplastic polyp and carcinoma of the colorectum
###end article-title 110
###begin article-title 111
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Alteration of O-6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients
###end article-title 111
###begin article-title 112
Immunohistochemical demonstration of p53 protein in colorectal adenomas and adenocarcinomas. Reliable application of the heat-induced antigen retrieval method to formalin-fixed, paraffin-embedded material
###end article-title 112
###begin article-title 113
Villous tumor of the colon and rectum with special reference to roles of p53 and bcl-2 in adenoma-carcinoma sequence
###end article-title 113
###begin article-title 114
Adenomas of the colon: overexpression of p53 protein and risk factors
###end article-title 114
###begin article-title 115
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer
###end article-title 115
###begin article-title 116
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
###end article-title 116
###begin article-title 117
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 39 74 39 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">methylguanine-DNA methyltransferase</italic>
###xml 133 138 <span type="species:ncbi:9606">human</span>
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
###end article-title 117
###begin article-title 118
Methylation of 0-6-Methylguanine DNA Methyltransferase characterises a subset of colorectal cancer with low level DNA microsatellite instability
###end article-title 118
###begin article-title 119
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 52 87 52 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">methylguanine-DNA methyltransferase</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 165 170 <span type="species:ncbi:9606">human</span>
Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis
###end article-title 119
###begin article-title 120
Frequent p53 gene mutations in serrated adenomas of the colorectum
###end article-title 120
###begin article-title 121
Molecular determinants of dysplasia in colorectal lesions
###end article-title 121
###begin article-title 122
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</italic>
###xml 37 38 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</italic>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>6</italic></sup>
###xml 38 74 38 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-Methylguanine-DNA Methyltransferase</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
Inactivation of the DNA repair gene 06-Methylguanine-DNA Methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis
###end article-title 122
###begin article-title 123
###xml 25 30 <span type="species:ncbi:9606">human</span>
Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC to AT transition mutations
###end article-title 123
###begin article-title 124
O-6-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C to A:T transitions
###end article-title 124
###begin article-title 125
MGMT promoter methylation and field defect in sporadic colorectal cancer
###end article-title 125
###begin article-title 126
###xml 68 73 <span type="species:ncbi:9606">human</span>
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
###end article-title 126
###begin title 127
Abbreviations
###end title 127
###begin p 128
colorectal cancer
###end p 128
###begin p 129
hyperplastic polyp
###end p 129
###begin p 130
O-6-methylguanine DNA methyltransferase
###end p 130
###begin p 131
mixed polyp
###end p 131
###begin p 132
serrated adenoma
###end p 132
###begin p 133
sessile serrated adenoma
###end p 133
###begin p 134
tubular adenoma
###end p 134
###begin p 135
tubulo-villous adenoma
###end p 135
###begin p 136
villous adenoma
###end p 136

